sleep, dementia, cardiovascular disease - brief notes

Journal articles:

Association of sleep duration in middle and old age with incidence of dementia (2021)
https://www.nature.com/articles/s41467-021-22354-2

- an epidemiological study followed people for 25 years and found those who reported sleeping 6 hours or less per night had 30% higher risk of dementia relative to those who reported sleeping at least 7 hours, on average

Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women (2021)
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab151/6239256

- a polysomnography study found higher all-cause and cardiovascular disease associated with higher arousal burden (a measure of unconscious wakefulness) for women, associations were less strong for men; potential for arousal burden as a biomarker & modifiable risk factor

News articles:

Sleeping Too Little in Middle Age May Increase Dementia Risk, Study Finds (2021)
https://www.nytimes.com/2021/04/20/health/sleep-dementia-risk.html

- two researchers not involved in the Nature study indicated that it provides evidence of causation since the sleep changes were recorded earlier (25 years before symptoms) than it is thought that brain pathology changes such as plaque accumulation occur (around 15-20 years prior to onset of symptoms)


Middle-aged people who sleep six hours or less at greater risk of dementia, study finds (2021)
https://www.theguardian.com/society/2021/apr/20/middle-aged-people-who-sleep-six-hours-or-less-at-greater-risk-of-dementia-study-finds

- researcher quoted in this article notes that disrupted sleep is a prodromal symptom and not necessarily a cause

 

One explanation for the link between short sleep duration and dementia is that during sleep the glymphatic drainage system clears waste from the brain and lack of sleep results in reduced clearance and build-up of protein aggregates.

The Glymphatic System: A Beginner's Guide (2015)
https://pubmed.ncbi.nlm.nih.gov/25947369/

However, dysfunction of the locus coeruleus could result in sleep problems and as well as alterations in microvascular circulation. Changes in microvascular circulation have been  implicated in both pathogenesis of neurodegeneration and normal brain aging.

mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer's disease (2021)
https://pubmed.ncbi.nlm.nih.gov/33888602/

"Failure of the blood flow response to neuronal activation (neurovascular coupling, NVC) in a model of AD precedes the onset of AD-like cognitive symptoms and is driven, to a large extent, by mTOR-dependent inhibition of nitric oxide synthase activity. Our studies show that mTOR also drives AD-like failure of non-NO-mediated components of NVC, and importantly that it suppresses NVC in non-diseased animals. Thus, mTOR attenuation may serve to treat AD, where we find that nNOS is profoundly reduced early in disease progression, and potentially other neurological diseases of aging with cerebrovascular dysfunction as part of their etiology. Our studies also provide, to our knowledge, the first evidence for a role of mTOR in regulating NVC in non-diseased conditions in mice."

Unfortunately, the above article is paywalled and I have no means to access it. The following, however, is open-access, as are the other articles linked in this post:

mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging (2019)
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acel.13057

 

The following review discusses the role of degeneration of the locus coeruleus in neuroinflammation and pathogenesis of dementia, Alzheimer's and Parkinson's:

Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia (2020)
https://pubmed.ncbi.nlm.nih.gov/33207731/

"Locus Coeruleus (LC) is the main noradrenergic nucleus of the central nervous system, and its neurons widely innervate the whole brain. LC is severely degenerated both in Alzheimer's disease (AD) and in Parkinson's disease (PD), years before the onset of clinical symptoms, through mechanisms that differ among the two disorders. 

...

New imaging and biochemical tools have recently been developed in humans to estimate in vivo the integrity of LC, the degree of neuroinflammation, and pathology AD/PD biomarkers; it is auspicable that these will allow in the near future to test the existence of a link between LC-neuroinflammation and neurodegeneration directly in patients." 

Comments

Popular posts from this blog

Notes - week of 2020/10/26

mouse models of menopause / reproductive aging in social insects - brief notes

Aconitase

geomagnetic fields, space, heart rate variability, autoimmune disease - brief notes